RxDoctor Payments Data

Christa McColl, NP

Nurse Practitioner · Savannah, GANPI 1821701012

Payments from drug & device makers

$3,734in general payments, 2019–2025

Across 153 payments — averaging $24.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$484
  • Amgen$378
  • Mallinckrodt Hospital Products Inc.$370
  • Ardelyx, Inc.$331
  • Otsuka America Pharmaceutical, Inc.$273
  • Vifor Pharma, Inc.$259
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$3,43692%
  • Education$2998%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,734 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$27,525
Medicare patients
124
Services billed
342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VeltassaPatiromer Calcium Sorbitex26$28,040
FarxigaDapagliflozin Propanediol39$23,374
ProsolParenteral Amino Acid 20% No.150$11,852
JardianceEmpagliflozin14$8,261
Midodrine Hcl20$1,597
Febuxostat14$1,175
Nifedipine ErNifedipine34$930
Bumetanide12$615
Nebivolol Hcl13$332
Losartan Potassium33$324
Telmisartan16$290
Spironolactone27$260
Calcitriol44$237
Furosemide56$202
Chlorthalidone22$187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$484$23,37439 claims
Boehringer IngelheimJardiance$40$8,26114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →